Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 4

The many faces of testosterone

Authors Jerald Bain

Published Date January 2007 Volume 2007:2(4) Pages 567—576

DOI http://dx.doi.org/10.2147/CIA.S1417

Published 3 January 2007

Jerald Bain

Department of Medicine, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, Mount Sinai Hospital, Toronto, Ontario, Canada

Abstract: Testosterone is more than a “male sex hormone”. It is an important contributor to the robust metabolic functioning of multiple bodily systems. The abuse of anabolic steroids by athletes over the years has been one of the major detractors from the investigation and treatment of clinical states that could be caused by or related to male hypogonadism. The unwarranted fear that testosterone therapy would induce prostate cancer has also deterred physicians form pursuing more aggressively the possibility of hypogonadism in symptomatic male patients. In addition to these two mythologies, many physicians believe that testosterone is bad for the male heart. The classical anabolic agents, 17-alkylated steroids, are, indeed, potentially harmful to the liver, to insulin action to lipid metabolism. These substances, however, are not testosterone, which has none of these adverse effects. The current evidence, in fact, strongly suggests that testosterone may be cardioprotective. There is virtually no evidence to implicate testosterone as a cause of prostate cancer. It may exacerbate an existing prostate cancer, although the evidence is flimsy, but it does not likely cause the cancer in the first place. Testosterone has stimulatory effects on bones, muscles, erythropoietin, libido, mood and cognition centres in the brain, penile erection. It is reduced in metabolic syndrome and diabetes and therapy with testosterone in these conditions may provide amelioration by lowering LDL cholesterol, blood sugar, glycated hemoglobin and insulin resistance. The best measure is bio-available testosterone which is the fraction of testosterone not bound to sex hormone binding globulin. Several forms of testosterone administration are available making compliance much less of an issue with testosterone replacement therapy.
Keywords: testosterone, androgens, male hypogonadism, anabolic steroids

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Nanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effect

Pal A, Talukdar D, Roy A, Ray S, Mallick A, Mandal C, Ray M

International Journal of Nanomedicine 2015, 10:3499-3518

Published Date: 12 May 2015

Neuroinflammation in Alzheimer’s disease

Zhang FJ, Jiang LL

Neuropsychiatric Disease and Treatment 2015, 11:243-256

Published Date: 30 January 2015

β-blockers: a novel class of antitumor agents

Ji Y, Chen S, Xiao X, Zheng S, Li K

OncoTargets and Therapy 2012, 5:391-401

Published Date: 26 November 2012

Modified supracricoid laryngectomy: oncological and functional outcomes in the elderly

Allegra E, Franco T, Trapasso S, Domanico R, La Boria A, Garozzo A

Clinical Interventions in Aging 2012, 7:475-480

Published Date: 8 November 2012

Antimicrobial and osteogenic effect of Ag-implanted titanium with a nanostructured surface

Zheng Y, Li J, Liu X, Sun J

International Journal of Nanomedicine 2012, 7:875-884

Published Date: 21 February 2012

The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals

Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL

International Journal of Nanomedicine 2011, 6:3125-3137

Published Date: 2 December 2011

Risk of “silent stroke” in patients older than 60 years: risk assessment and clinical perspectives

Jae-Sung Lim, Hyung-Min Kwon

Clinical Interventions in Aging 2010, 5:239-251

Published Date: 2 September 2010

Management of the behavioral and psychological symptoms of dementia

Elizabeth C Hersch, Sharon Falzgraf

Clinical Interventions in Aging 2007, 2:611-621

Published Date: 3 January 2007